Print this Article
RSSBusiness Wire
Health Sciences Group, Inc. (OTCBB: HESG), provider of innovative nutritional products and ingredients derived from natural sources, announced today that it has received resounding positive feedback from consumers, retailers and industry participants on its innovative new products which debuted at the Natural Products Expo West in Anaheim. Swiss Research, a division of Health Sciences Group, Inc. showcased its two flagship products targeting the weight management and heart health markets:
-- Shugr(TM) - a natural, zero-calorie sugar substitute, formulated with GRAS-certified ingredients which tastes like sugar, cooks like sugar and is diabetic-safe; and
-- Sequestrol(TM) - a proprietary nutritional supplement and functional ingredient which is clinically proven to assist in the reduction of low-density lipoprotein (LDL) cholesterol and triglyceride levels.
"We are very pleased with the overwhelming response we have received for our products at Expo West," commented Fred E. Tannous, Co-chairman and CEO of Health Sciences Group. "Not only did we receive numerous inquiries from consumers, but we have actually entered into negotiations with several major retailers and distributors for our Shugr product, which we expect to turn into orders fairly soon."
Sequestrol, the company's natural cholesterol-lowering nutritional supplement, also garnered attention. The active ingredient in Sequestrol, low molecular weight polymannuronate, is derived from brown seaweed and kelp using a patented extraction method. Much of the attention focused on its effectiveness in reducing serum and liver cholesterol as well as controlling serum and liver triglyceride levels. In a one study it was found to reduce cholesterol level in all patients by 22.7%.
"The clinically-proven efficacy of Sequestrol gives us a competitive advantage when compared with other natural products on the market today," commented Bill Glaser, Co-chairman and President of Health Sciences Group. "We believe the tremendous response we are receiving for Sequestrol is a positive indication for its future sales prospects. We expect to initially distribute Sequestrol through direct marketing channels, such as radio and television infomercials. In fact, we are currently in discussions with several direct response companies for the development of the Sequestrol campaign. With over 136 million Americans watching one form of direct response television or another, we believe that a Sequestrol infomercial presents a tremendous opportunity to generate significant revenues for Health Sciences Group."
About Health Sciences Group, Inc.
Health Sciences Group identifies, develops and commercializes innovative nutritional products and functional ingredients derived from natural sources to provide consumers and medical professionals with preventative healthcare alternatives. The company markets its own line of proprietary products based on novel technologies with clinically-supported, GRAS-certified ingredients under its Swiss Research(TM) and Swiss Diet(TM) brand names.
For more information, visit www.HSciences.com, www.SwissDiet.com, and www.Shugr.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including without limitation, the independent authority of the special committee to act on the matters discussed, the successful negotiation of the potential acquisition and disposal of transactions described above, successful implementation of the company's business strategy and competition, any of which may cause actual results to differ materially from those described in the statements. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.
